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Fetal testis is a major target of endocrine disruptors (EDs). During the last 20 years, we have developed an organotypic culture system that
maintains the function of the different fetal testis cell types and have used this approach as a toxicological test to evaluate the effects of
various compounds on gametogenesis and steroidogenesis in rat, mouse and human testes. We named this test rat, mouse and human fetal
testis assay. With this approach, we compared the effects of six potential EDs ((mono-(2-ethylhexyl) phthalate (MEHP), cadmium, depleted
uranium, diethylstilboestrol (DES), bisphenol A (BPA) andmetformin) and one signalling molecule (retinoic acid (RA)) on the function of rat,
mouse and human fetal testis at a comparable developmental stage. We found that the response is similar in humans and rodents for only
one third of our analyses. For instance, RA and MEHP have similar negative effects on gametogenesis in the three species. For another third
of our analyses, the threshold efficient concentrations that disturb gametogenesis and/or steroidogenesis differ as a function of the species.
For instance, BPA and metformin have similar negative effects on steroidogenesis in human and rodents, but at different threshold doses. For
the last third of our analyses, the qualitative response is species specific. For instance, MEHP and DES affect steroidogenesis in rodents, but
not in human fetal testis. These species differences raise concerns about the extrapolation of data obtained in rodents to human health risk
assessment and highlight the need of rigorous comparisons of the effects in human and rodent models, when assessing ED risk.
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In regulatory toxicology, the human health risk from
exposure to a given endocrine disruptor (ED) is
classically assessed using animal, especially rodent,
models followed by an extrapolation of the data to
humans. Generally, to define the regulatory acceptance
for human health, the lowest no observed adverse effect
level (NOAEL) measured in the rodent model is divided
by a safety factor equal to ten to account for the
difference between rodents and humans and by an
additional tenfold uncertainty factor to account for inter-
individual differences in susceptibility.
However, differently from fundamental processes
such as cell differentiation, mitosis and carcinogenesis,This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
R120 R Habert and othersmany endocrine processes largely vary from one species
to another. These species differences are even more
pronounced for reproductive functions. Thus, the rele-
vance of extrapolating animal data to human risk
assessment should be questioned when assessing ED
effects on reproductive functions.
The incidence of abnormalities of the male reproduc-
tive function has been increasing over the years
(reviewed in Sharpe & Irvine (2004), Leridon & Slama
(2008), and Main et al. (2010)). Human sperm count has
been markedly decreasing and the rate of testicular
cancer has clearly increased over the past four decades.
Moreover, the prevalence rates of cryptorchidism and
hypospadias are also probably increasing. More epide-
miological, clinical and experimental data suggest that
these male reproductive disorders could be due at least
in part to the effects of EDs, which are becoming ever
more concentrated and prevalent in our environment
(Sharpe & Skakkebaek 1993, reviewed in Delbe`s et al.
(2006) and Vandenberg et al. (2012)). Furthermore, it has
been hypothesized that these alterations are symptoms
of a single syndrome named ‘testicular dysgenesis
syndrome’ (TDS), resulting from abnormalities in testis
development during fetal life (Skakkebaek et al. 2001,
Olesen et al. 2007). Thus, the fetal testis is a very relevant
target to study the species differences in ED effects.
Fetal testis performs two major functions: gameto-
genesis and steroidogenesis (reviewed in Olaso & Habert
(2000), Habert et al. (2001), and O’Shaughnessy & Fowler
(2011)). Sertoli cells, which surround germ cells to form
the seminiferous cords, are the first to differentiate at
11.5 days post-conception (dpc) in mice, 13.5 dpc in rats
and 42–45 dpc in humans. Sertoli cells divide actively
until puberty and then remain quiescent. In adult life,
sperm production will depend on the number of Sertoli
cells formed during this period (reviewed in Sharpe
(2012)). In the early fetal testis, germ cells originated
from migrating primordial germ cells, which are named
gonocytes, proliferate. In rodents, they enter synchro-
nously a quiescent period during which mitosis and
apoptosis are arrested so that the number of gonocytes
does not change (from 18.5 dpc to 3–4 days post-partum
(dpp) in rats and from 15.5 dpc to 0–1 dpp in mice).
In humans, from the beginning of the second trimester,
gonocytes progressively differentiate into prespermatogo-
nia (also called prospermatogonia or fetal spermatogonia)
that no longer express C-KIT and OCT4 (Franke
et al. 2004, Gaskell et al. 2004), similar to rodent germ
cells during late neonatal life. These cells enter non-
simultaneously a quiescent period for one group (Gaskell
et al. 2004) whereas, for another group, some of these
cells go on cell cycle (Pauls et al. 2006). Importantly,
the differentiation of germ cells is not synchronous so
that, even if each germ cell entered a quiescent period,
the total number of germ cells per testis continuously
increases during the whole fetal life in humans. As
gonocytes give rise to the adult spermatogonial stem cellsReproduction (2014) 147 119–129during neonatal life, correct development of the germ
cell lineage during fetal/embryonic life is essential for the
production of spermatozoa during adult life. Fetal Leydig
cells differentiate soon after Sertoli cells and produce
testosterone and insulin-like factor 3 (INSL3) that are
required for the embryo phenotypic masculinization
(reviewed in Scott et al. (2009) and Bay et al. (2011)).
In the 1990s, we developed an organotypic culture
system, which we named fetal testis assay (FeTA; Habert
et al. 1991, Lecerf et al. 1993, Olaso et al. 1998, Livera
et al. 2000), that allows maintaining both gametogenesis
and steroidogenesis of the rat fetal testis explants for a
few days. We have adapted the system to mouse and
human fetal testes over the past 10 years and this system
allows a rigorous inter-species comparison of the fetal
testis responsiveness and susceptibility to various
chemicals. We review here data obtained for several
EDs, the anti-diabetic drug metformin and retinoic acid
(RA), a major paracrine/autocrine factor in fetal testis,
covering a broad spectrum of genes and pathways
potentially targeted by the chemicals and involved in
toxicant-induced phenotypes.An experimental model to compare human, mouse
and rat fetal testis responsiveness
Choice of the system
One simple ethically acceptable way to evaluate directly
the effect of a chemical compound in the human species
is the use of in vitro approaches. However, the main
limitation of toxicological studies using in vitro systems
is the inability to reproduce the in vivo cell activities
and fates. For instance, in cell culture systems, fetal
Leydig cells dedifferentiate in the absence of specific
gonadotropic stimulation (Habert & Brignaschi 1991,
Rouiller-Fabre et al. 1998) and isolated gonocytes do not
survive well (Boulogne et al. 2003). Organ culture
systems in which the testis architecture and intercellular
communications are preserved appeared to us to be a
relevant method to maintain the development of fetal or
neonatal testis. In the 1990s, we compared different
in vitro systems and found that the best functional and
histological results were obtained by placing rat fetal
testis explants on a membrane that floats on the culture
medium at the air–medium interface (Habert et al. 1991).
This organotypic culture system allows reproducing
in vitro the normal development of testis somatic and
germ cells without addition of any exogenous signalling
factor (Habert et al. 1991, Lecerf et al. 1993, Olaso
et al. 1998, Livera et al. 2000). We then adapted this
methodology also to the culture of mouse and human
fetal testes (Lambrot et al. 2006a, Livera et al. 2006).
We then validated this organotypic culture system under
the name of rat, mouse and human FeTA (r/m/h FeTA) as
a tool to study the age-, time- and dose-dependent direct
effects of various compounds on fetal testis functions andwww.reproduction-online.org
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Figure 1 The fetal testis assay (FeTA). Human (6–12 GW), rat (14.5 dpc)
or mouse (12.5 dpc) fetal testes are cultured on Millicell-CM Biopore
membranes (pore size 0.4 mm, Millipore, Billerica, MA, USA) floating
on 320 ml culture medium in tissue culture dishes at 37 8C in a
humidified atmosphere containing 95% air/5% CO2. The culture
medium is phenol red-free DMEM/Ham F12 (1:1) without biological
factors and hormones. The culture medium is completely changed
every 24 h. Whole mouse and rat testes are cultured on the membrane,
while human testes are cut into small pieces (around 0.2 mm3) due to
their larger size and three to four pieces are randomly placed on the
membrane (two to eight wells per testis). The secretion of various
molecules in the medium (testosterone, INSL3, AMH, transferrin,
lactate, etc.) can be quantified every day. At the end of the culture,
explants can be fixed and tissue sections can be used to assess, for
instance, the total number of cells per testis, apoptotic activity (cleaved
caspase 3, TUNEL assay) or mitotic activity (Ki67, BrdU incorporation),
expression of Leydig cell (steroidogenic actors, INSL3, LH Receptors,
etc.), Sertoli cell (AMH, SOX9, etc.) and germ cell markers
(pluripotency genes, such as OCT3-4, NANOG and differentiation
genes such as c-KIT, NANOS2 and DNMT3L).
From rodent data to human risk assessment R121development (Lambrot et al. 2006b). This organotypic
culture system has also been used by others for rat (Cupp
& Skinner 2001, Li & Kim 2003, Stroheker et al. 2006,
Chauvigne´ et al. 2009) and human testis explants
(Bendsen et al. 2001, Robinson et al. 2003, Hallmark
et al. 2007). Recently, we also showed that the r/m/h
FeTA assay is a valuable toxicological assay by
demonstrating that the in vivo effects of mono-2-
ethylhexyl phthalate (MEHP) during mouse fetal testis
development could be reproduced in our culture system
(Muczynski et al. 2012). The hFeTA assay and the
histological features of human fetal testis explants at the
end of the culture period are presented in Figs 1 and 2.When to do the explants?
Using this culture system, we observed clear age-related
changes in the fetal testis responsiveness to various
compounds. For instance, gonadotropin-releasing hor-
mone (GNRH), a putative paracrine testicular factor,
does not have any effect on testosterone secretion in 14.5
dpc rat fetal testes, whereas it has negative effects inwww.reproduction-online.org16.5–18.5 dpc testes and positive effects in testis
explants from 20.5 dpc onwards (Habert et al. 1991).
Oestradiol and diethylstilboestrol (DES) reduce testoster-
one production in 14.5 dpc rat fetal testis explants, but
not in older specimens (Delbe`s et al. 2007). Similarly,
the development of the germ cell lineage is affected
differently as a function of age. MEHP apoptotic effect on
gonocytes is much stronger in 11.5–13.5 dpc mouse fetal
testis explants than in neonatal ones (Lehraiki et al.
2009). Age-related changes in the gonocyte response to
various factors (RA, triiodothyronine, phorbol ester) have
also been observed in cultures of dispersed testicular
cells (Boulogne et al. 2003). Thus, to compare different
species, it is necessary to choose a similar stage of
development. We obtained human fetal testis samples
from abortions carried out between the 6th and the 12th
gestational week (GW), which corresponds to a period
when testosterone secretion is increasing and gonocytes
are proliferating (Rouiller-Fabre et al. 2009). To compare
age-matched fetal testes from the three species, we
decided to use 14.5 dpc rat (Habert & Picon 1984,
Boulogne et al. 1999) and 12.5 dpc mouse testes
(Vergouwen et al. 1991, Livera et al. 2006).Choice of culture conditions
Steroidogenesis can be measured using two parameters:
i) the basal secretion of testosterone (i.e. in the absence of
placental leutenizing hormone (LH) or human chorionic
gonadotropin, hCG) that, in short-term cultures, reflects
the in vivo testis activity (Habert & Picon 1982) and ii) the
secretion of testosterone in the presence of LH/hCG to
measure the explant maximum steroidogenic capacity.
In utero decapitation of 16.5–18.5 dpc rat fetuses, a
surgical operation that suppresses LH in fetal plasma and
that is compatible with embryo survival, reduces basal
but not LH-stimulated testosterone secretion in vitro,
showing that endogenous LH is necessary for basal in vivo
steroidogenic activity but not for the differentiation of
Leydig cells (Migrenne et al. 2001). Moreover, in 18.5 dpc
rat testis explants, addition of a GNRH agonist increases
the basal secretion and decreases the LH-stimulated
secretion of testosterone (Habert et al. 1991). Thus, when
comparing the effect of a compound in different species,
it is important to use the same parameters (basal or
LH-stimulated testosterone secretion).Strengths and limits of the FeTA
The advantages of the organotypic culture system to
study the chemical effects are numerous. This method
allows the investigation of direct effects of chemicals
alone or in mixture upon the fetal testis development and
function. It allows a precise study of their kinetics of
action and the duration and level of exposure is precisely
controlled. These cultures are carried out in a definedReproduction (2014) 147 119–129
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Figure 2 Immunohistological features of human fetal testis explants after culture. (A) AMH expression. In tissue sections from a ten GW human testis
explant, Sertoli cells were immunostained with anti-AMH antibodies (brown cytoplasm). Gonocytes are identified as white cells inside the
seminiferous cords. Bar: 10 mM. (B) Double immunofluorescence for AMH and M2A (9.5 GW human testis explants). M2A staining (green) is
exclusively localized in gonocytes, characterized as large seminiferous cells that do not express AMH, a marker of Sertoli cells (red). Scale bar:
10 mM. (C) Cytochrome P450 scc expression. (9 GW human testis explant). Leydig cells are identified by cytochrome P450 scc expression. They are
localized in the interstitial tissue between the seminiferous cords, which are here delineated by a dotted line. Scale bar: 20 mM. (D) Double
immunostaining for AMH and Ki67 (7.5 GW human testis explant). Sertoli cells are identified by AMH expression (brown) and cycling cells are Ki67-
positive (purple). Black arrow: Ki67-negative gonocyte. White arrow: Ki67-positive gonocyte. White arrowhead: Ki67-negative Sertoli cell. Black
arrowhead: Ki67-positive Sertoli cell. Scale bar: 10 mM. (E) Double immunostaining for AMH and BrdU (10.7 GW human testis explant). BrdU was
added 2 h before the end of the culture. Sertoli cells are identified by AMH expression (purple) and cycling cells in S phase are detected by
immunostaining for BrdU (brown). Black arrow: BrdU-negative gonocyte. White arrow: BrdU-positive gonocyte. Scale bar: 10 mM. (F) Double
immunostaining for AMH and TUNEL (11.5 GW human testis explant). Sertoli cells are identified by AMH expression (brown cytoplasm) and
gonocytes as cells with white cytoplasm inside the seminiferous cords. Apoptotic cell are identified by TUNEL assay (brown nucleus). Black arrow:
TUNEL-negative gonocyte. White arrow: TUNEL-positive gonocyte. Scale bar: 10 mM. (G) Double immunostaining for AMH and cleaved caspase 3
(ten GW human testis explant). Sertoli cells are identified by AMH expression (purple cytoplasm) and gonocytes as cells with white cytoplasm inside
the seminiferous cords. Apoptotic cell are identified by immunostaining for cleaved caspase 3 (brown nucleus). Black arrow: caspase 3-negative
gonocyte. White arrow: caspase 3-positive gonocyte. Scale bar: 10 mM.
R122 R Habert and othersmedium (usually with no phenol red), thus avoiding
cross-contamination with other biologically active
molecules. The treated testicular explants are compared
with explants issued from the same testis (when the fetal
testes are large enough to be cut into different pieces,
i.e. with human or older rodent testes) or with the
contralateral testis from the same fetus (for 14.5–15.5
dpc rat and 12.5–13.5 dpc mouse fetuses) that are
cultured with vehicle only and served as controls. This
paired analysis limits individual variability and increases
the sensitivity of the method. As pregnant rodent females
can produce up to 15 embryos, it is possible to assay
various doses or different compounds with a single
pregnant female, thus reducing the number of animals
killed in comparison with in vivo approach. FeTA is also
largely less time- and labour-intensive and cheaper than
in vivo approaches. FeTA is a convenient model to
investigate the mechanism of action of ED. The use of
fetal testes from transgenic mice easily allows the
identification of the pathway involved in chemicalReproduction (2014) 147 119–129effects. As an example, unlike the DES effect, the
negative effect of bisphenol A (BPA) on testosterone
produced by the WT mouse fetal testis was maintained
when using an ERaKO fetal testis. This suggests a specific
signalling pathway for BPA, which does not involve ERa
and differs from the DES mode of action (Delbe`s et al.
2005, N’Tumba-Byn et al. 2012). Interestingly, such an
experimental approach allows the use of transgenic mice
in which knocking out the gene is lethal during gestation.
Indeed, this method allows the maintenance of the
development of the testis even beyond the death of the
fetus (Petre-Lazar et al. 2007). Lastly, as shown in this
paper, FeTA brings a valuable help in the translation of
animal data to human beings.
As with each model, FeTA also has inherent limits. The
main one is that long-term effects cannot be studied
using this system as the development of the testis is
maintained in vitro only for a few days (w4–10 days
depending on the species, the stage at sampling and the
studied endpoint). Especially, this drawback is significantwww.reproduction-online.org
From rodent data to human risk assessment R123for the overall study of fetal gametogenesis in the human
species that is a slow process. Xenograft of human fetal
testes into immunodeficient rodent allows such long-
term studies (Mitchell et al. 2010). However, for human
fetal testicular steroidogenesis, there is no advantage in
using the xenograft model in comparison with organo-
typic culture as the former is highly more time-, money-
and animal-intensive and displays a higher variability
than the latter. Furthermore, the metabolism of the
chemicals in the rodent host can differ from that in
humans. FeTA is a system that does not permit the study
of delayed effect such as abnormal spermatogenesis.
Such long-term effects that may result from alterations
of the differentiation of the gonocytes that are the
precursors of spermatogonia stem cells must be studied
in vivo. Another drawback of the in vitro approach is that
this method only allows study of the direct effect without
considering the potential extra testicular feedback
loops that could compensate the effects of exogenous
chemicals. Moreover, it does not take into account
the indirect effect that these molecules can exert, for
instance via a change in the activities of the placenta
or of the hypothalamo–hypophysis axis that are known
to play a role in testis development.Human Rat Mouse
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www.reproduction-online.orgSpecies-dependent effects of various chemical
compounds on fetal testis function
Using the r/m/h FeTA system, we compared the effects
of seven compounds on gametogenesis and steroido-
genesis in rat, mouse and human fetal testes explants.
Results are summarized in Fig. 3.Phthalates
In vivo models have shown that phthalates impair
gonocyte development in the rat (Barlow et al. 2003,
Ferrara et al. 2006, reviewed in Habert et al. (2009)).
Increased gonocyte apoptosis was also observed in vitro
using the FeTA system in rat, mouse and human fetal
testis explants (Chauvigne´ et al. 2009, Lambrot et al.
2009, Lehraiki et al. 2009). Conversely, MEHP induced
the appearance of multinucleated gonocytes only in
mouse and rat but not in human fetal testis explants.
Moreover, MEHP did not affect testosterone production
in human fetal testis explants (Lambrot et al. 2009).
This was surprising because phthalates are considered
anti-androgenic compounds based on their inhibitory
action on in vivo production of testosterone in the rat 
Human Rat Mouse
No No No
No Negative Positive
No Negative Positive
No No No
Negative No No
Negative No No
Negative – No
Negative Negative Negative effect
No Negative Negative
No Negative Negative
– – –
– – –
No – No
– – –
No – No 
No – No 
No – No 
Negative – No
Negative – Slightly negative
Negative – Negative
Negative – Negative
– No –
sitive (<7GW)
 no (>7GW) Negative Positive
Species
Effect on Leydig cell function
Lambrot et al. (2009), Lehraiki et al. (2009),
Muczynski et al. (2012), Data in this paper.
References
Livera et al. (2000), Lambrot et al. (2006a,b),
Trautman et al. (2008), Livera G, Grisin T,
Guerquin MJ & Habert R (personal data)
N'Tumba-Byn et al. (2012)
Delbès et al. (2006), N'Tumba Byn et al. (2012),
Habert R, Lambrot R, Grisin T, Moison D,
Livera G & Rouiller-Fabre V (personal data)
Angenard et al. (2010)
Angenard et al. (2011)
Tartarin et al. (2012)
steroidogenesis in human, rat and mouse fetal testis. Testes from 6 to 12
r 4 days as described in the legend of Fig. 1. The culture medium, which
very 24 h. Germ cell development was assessed at the end of the culture
rate (percentage of TUNEL-positive or caspase 3-positive gonocytes) and
medium for the last 2 h of culture). Leydig cell function was assessed by
ative: the chemical reduces the number of gonocytes (and/or increases
roduction; positive: the chemical increases the number of gonocytes
s testosterone production; –: not performed. White area: the response is
milar in human and rodent testes, but the NOAEL is different. Black area:
Reproduction (2014) 147 119–129
D1 D2 D3 
Culture period (day)
0
20
40
60
80
100
120
D1 D2 D3
0
50
100
150
200
A
B
Human
MEHP 10–4 M 
MEHP 10–6 M 
MEHP 10–5 M 
Rat 
Culture period (day)
Te
st
os
te
ro
ne
 s
ec
re
tio
n
(%
 of
 un
tre
ate
d e
xp
lan
ts)
Te
st
os
te
ro
ne
 s
ec
re
tio
n
(%
 of
 un
tre
ate
d e
xp
lan
ts)
***
**
**
*
Figure 4 Effect of MEHP on testosterone secretion by cultured rat and
human fetal testis explants. Testes from 7 to 11 GW human fetuses (A)
to 14.5-day-old rat fetuses (B) were cultured using the FeTA system,
a method in which the explants are deposited on floating membrane
at the interface between air and medium that we had previously
developed for the rats (Habert et al. 1991, Lecerf et al. 1993) and
humans (Lambrot et al. 2006a,b). This method is briefly described in the
legend of Fig. 1. Culture medium, which did not contain biological
factors or hormones, was completely changed every 24 h. For each
fetus, after 24 h of culture in control medium (D0), one testis was
cultured in the absence (untreated) and the other one in the presence
of MEHP at concentrations ranging from 10K6 to 10K4 M for 3 days
(D1–D3). The daily testosterone secretion was measured by radio-
immunoassay and the values at D1–D3 were normalized to the D0
secretion of the same testicular explant. Values (meanGS.E.M.) were
then expressed as the percentage of the normalized secretion of the
treated explant compared with that of the untreated explant. For human
samples, nZ3 for 10K6 M, nZ3 for 10K5 M and nZ15 for 10K4 M.
For rat samples, nZ5–7 for the three concentrations. *P!0.05,
**P!0.01, ***P!0.001 compared with untreated testis using the
Wilcoxon’s non-parametric paired test. Values for human testis cultures
are from Lambrot et al. (2009).
R124 R Habert and others(reviewed in Habert et al. (2009) and Scott et al. (2009)).
One explanation could be that in vitro systems are
unsuitable for detecting the anti-androgenic effects of
phthalates. Indeed, some authors found that addition of
MBP or MEHP to cultured rat fetal testes do not affect
testosterone production (Stroheker et al. 2006, Hallmark
et al. 2007). Conversely, MEHP increased or did not
change the basal or LH-stimulated testosterone pro-
duction by mouse fetal testis explants in the FeTA system
(Lehraiki et al. 2009). However, another study reported a
MEHP-induced reduction of testosterone secretion by
fetal rat testes cultured in the FeTA system (Chauvigne´
et al. 2009). This effect could be observed when only half
of the medium was changed daily, but not when the
medium was completely changed every 24 h (i.e. the
conditions we used for human testes in the study by
Lambrot et al. 2009). This made us question our
conclusion that phthalates are not anti-androgenic in
the human species. Thus, we recently re-evaluated the
effect of phthalates on testosterone production in rat fetal
testes cultured rigorously following the same conditions
as those we had used previously for human fetal testis
(i.e. daily change of the whole medium). Original data
are presented in Fig. 4B. We found that, unlike the results
of Chauvigne´ et al. (2009), MEHP induced a dose- and
time-dependent decrease in testosterone production in
cultured rat fetal testis explants (Fig. 4). Thus, the rat
model can be used as a positive control to validate the
absence of phthalate effects on the steroidogenic
response in human testis explants. Furthermore, we
confirmed that MEHP increases germ cell apoptosis as
the percentage of caspase 3-positive cells increased from
0.86G0.25 in controls to 8.14G0.13 in 10K4 M MEHP-
treated testes at day 3 (D3) of culture. We cannot explain
why Chauvigne´ et al. (2009) could not observe
a steroidogenic effect of MEHP with a complete daily
change of the medium. Nevertheless, this emphasizes
that inter-species comparisons need to be carried
out following a rigorous approach: i) selecting ages of
gestation where the same events are occurring, ii) using
an identical method across the different species that
supports gametogenesis and steroidogenesis, iii) using
explants with very similar size, iv) using explants that
are not contaminated with mesonephros and v) reducing
experimentation variability by using the same investi-
gators and the same material.
The recent observations that di-n-butyl phthalate
decreases steroidogenic activity in rat fetal testes but
not in human fetal testes grafted into a host mouse or
rat (Heger et al. 2012, Mitchell et al. 2012) definitively
confirms that phthalates are not anti-androgenic
compounds for human fetal testis.Bisphenol A
The FeTA system showed that the minimum BPA
concentration required to impair testosteroneReproduction (2014) 147 119–129production is at least 100-fold lower for human than
for rat and mouse fetal testes (N’Tumba-Byn et al. 2012).
Specifically, 0.01 mM BPA (i.e. a concentration relevant
to human internal exposure) is sufficient to decrease
testosterone production in human fetal testes, whereas
concentrations as high as 1 or 10 mM are necessary in
mouse and rat explants.www.reproduction-online.org
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cell function led to contradictory conclusions. Exposure
to high doses of BPA during pregnancy reduced
plasma testosterone at birth in the rat (Tanaka et al.
2006). Administration of low doses (50 mg/kg per day)
BPA to pregnant rats reduced the anogenital distance
(AGD) in male pups, whereas lower BPA doses had no
effect (Murray et al. 2007). To the contrary, three other
independent studies did not show any effect of BPA
on AGD after gestational administration of various
doses from 1 to 50 000 mg/kg per day (Kobayashi et al.
2002, Tyl et al. 2002, Howdeshell et al. 2008). In
humans, a recent retrospective epidemiological study
highlighted that sons of workers who were professionally
exposed to high levels of BPA during pregnancy had
shorter AGD (Miao et al. 2011). However, no increase
in BPA concentration in umbilical cord blood was
observed in newborns with cryptorchidism (Fenichel
et al. 2012).Diethylstilboestrol
The FeTA system showed that DES clearly impairs both
steroidogenesis and gametogenesis in rat and mouse,
but not human fetal testis explants (Delbe`s et al. 2007,
N’Tumba-Byn et al. 2012 and Habert R, Lambrot R,
Grisin T, Moison D, Livera G & Rouiller-Fabre V personal
data). This is puzzling because it has been reported
that in utero exposure to DES is associated with TDS
(hypospermia, testicular cancer, hypospadias and cryp-
torchidism), although the data about the increased risk
of testicular cancer following in utero DES exposure
remain conflicting (reviewed in Delbe`s et al. (2006) and
Mitchell et al. (2013)). The absence of DES effect on human
fetal testicular steroidogenesis was confirmed recently
using the xenograft model (Mitchell et al. 2013). This
suggests that DES effects in utero on human testes concern
endpoints that have not been yet studied, such as a direct
effect on the genital tract or INSL3 secretion. Alternatively,
it could impair the molecular differentiation of gonocytes
in such a way to produce a delayed effect that can be
detected onlyat later stages of development or in adult life.
Further studies are needed to address this point.Depleted uranium
To our knowledge, no data on the in vivo effect of
depleted uranium on the development of the fetal testis
are available. The effect of non-radioactive uranium was
assessed using the FeTA system only in human and
mouse testis explants (Angenard et al. 2011). Uranium,
even at high concentrations (100 mM), did not affect
testosterone production in both species. Conversely, it
decreased the number of gonocytes by inducing
apoptosis. The NOAEL is between 10 and 50 mM for
human testis and around 100 mM for mouse testis.www.reproduction-online.orgCadmium
The effects of cadmium were also compared only in
the human and mouse species using the FeTA system
(Angenard et al. 2010). Steroidogenesis was not affected
by cadmium in both species, whereas the number
of gonocytes was reduced by increased apoptosis. The
NOAEL ranges were between 0.1 and 1 mM for human
testis and between 1 and 10 mM for mouse testis. In vivo,
gonadal development in mouse embryos exposed to
cadmium in early organogenesis was studied by Tam &
Liu (1985). Genital ridge size was reduced in exposed
animals, with retarded germ cell migration into the ridges,
resulting in depleted populations of germ cells, defective
maturation of gametes and subfertility in male offspring.Metformin
Metformin is an anti-diabetic drug that is used to treat
gestational diabetes and polycystic ovary syndrome.
In the FeTA system, metformin reduces testosterone
secretion in both human and mouse testis explants, but
the NOAEL is !50 mM for human testis and around
500 mM for mouse testis (Tartarin et al. 2012). This result
is important because the 50 mM level is in the range of
concentrations measured in human plasma during
therapeutic treatment. In agreement with the in vitro
approach, daily administration of 300 mg/kg per day
metformin to pregnant mice from 0.5 dpc induced
a decrease in the fetal testicular testosterone content at
16.5 dpc (Tartarin et al. 2012).Retinoic acid
In the FeTA system, RA has a positive steroidogenic effect
in human fetal testes (but only when younger than 7 GW)
and in mouse fetal testes but a negative effect in rat fetal
testes (Livera et al. 2000, Lambrot et al. 2006a, Livera G &
Habert R personal data). Concerning gametogenesis, RA
increases mitosis but also apoptosis (more strongly) in
gonocytes; thus, the overall result was a decrease in the
total number of gonocytes in cultured rat, mouse and
human testis explants (Livera et al. 2000, Lambrot et al.
2006a, Trautmann et al. 2008, Guerquin MJ, Grisin T,
Habert R & Livera G personal data). Specifically, RA
induces meiosis in 12.5 dpc mouse explants, but not in
14.5 dpc rat explants and 6–12 GW human explants. This
difference may not be only a consequence of a shift in
developmental stage as the effect is retrieved with 11.5
dpc mouse testes but not in the 13.5 dpc rat testis. We
rather favour the hypothesis that male commitment is
governed by several pathways, the importance of which
varies from one species to another. In agreement with our
in vitro results, a mild vitamin A-deficient diet that results
in a threefold decrease in plasma retinol concentration in
pregnant rat increases the fetal testicular steroidogenesis
at 18.5 dpc. This study showed that the endogenousReproduction (2014) 147 119–129
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function of fetal Leydig cells in the rat species (Livera
et al. 2004). Similarly, the knockout of RA receptor a
(RARa) results in an increase in the number of germ cells
in mouse fetus (Livera G & Habert R personal data).
Furthermore, RA prevents germ cell mitotic arrest both
in vitro and in vivo (Trautmann et al. 2008).Conclusion
Over the past 10 years, we have compared the effects of
six EDs and of RA in rat, mouse and human fetal testis
explants using the r/m/h FeTA assay. The results show that
these compounds can be classified into three groups based
on the species-specific in vitro responses (Fig. 3). In the
first group (with white background in Fig. 3), the in vitro
response to a given compound is similar across the three
species. In the second group (with grey background in
Fig. 3), the response is qualitatively similar, but the NOAEL
is different. For instance, the effect of cadmium and
uranium on gonocyte development and the effect of BPA
and metformin on steroidogenesis are qualitatively similar
in three species, but the susceptibility is higher in humans
than in rodents. These species differences probably result
from differences in the expression of signalling pathways
or endogenous hormonal production. Particularly, when
considering the negative effect of BPA on steroidogenesis,
its NOAEL is more than 100-fold lower in humans than
in rodents. This raises concerns because the Sanitary
Agencies routinely apply a security factor of 100 when
extrapolating rodent data on BPA to human risk assess-
ment. The third group (with black background in Fig. 3)
includes compounds that show qualitative differences
in the three species: phthalate effect on steroidogenesis,
DES effect on gametogenesis and steroidogenesis and
RA effect on steroidogenesis. This suggests that there are
fundamental differences in the signalling pathways of
phthalates, DES and RA in humans and rodents. For
instance, the absence of DES effect in human fetal Leydig
cells can be explained by the fact that ERS1 is not
expressed in human fetal testis (Gaskell et al. 2003). More
detailed studies must be performed to evaluate the
endocrine differences and the various signalling pathways
and molecular targets in human and rodent testes.
Another surprising finding of this comparison is that
some compounds, such as phthalates and RA, can have a
stimulatory effect in mice and an inhibitory effect in rats.
This may result from species differences in the rate-limiting
steps of the steroid synthesis pathway or in the cellular
localization of steroidogenic enzymes. Indeed, aromatase
is mainly localized in Sertoli cells in rats and in Leydig
cells in mice (Borday et al. 2013).
In conclusion, our findings obtained using the r/m/h
FeTA assay show that the threshold of susceptibility to
chemicals differs between human and rodent fetal testes
for one third the tested compounds. Importantly, the very
existence of a response, whatever the dose of the chemical,Reproduction (2014) 147 119–129differs as a function of the species in another third of the
cases. Depending on the chemical and on the biological
function, its effect may be more intense or less adverse in
human than in rodent testes. This raises concerns about the
widespread use of rodent models to assess the adverse
effects of EDs on human health. This study highlights the
need to develop specific tools to study reprotoxicity
specifically in humans and the importance of widening
our knowledge on the molecular and endocrine
differences between human and rodent fetal testis.Discussion from meeting
Pia Juul Nielsen (Copenhagen, Denmark): Are you
indicating that you can use in vitro experimental studies
to predict adverse effects, but you cannot predict the
safe levels? You see responses in mice, rats and humans
but at different dose levels.
R Habert (Fontenay aux roses, France): In our in vitro
system named FeTA, the dose–response curve allows us
to clearly define the no observed adverse level (NOAEL)
and the lowest observed adverse effect level of one
endocrine disruptor (ED) acting directly on the fetal
testis. Obviously this is only one experimental approach
and the FeTA results must be compared with other
approaches to define the safe level in real life, which is
a very difficult challenge. Importantly, if in the FeTA
system, a given dose level of one compound shows no
effect in humans, but effects are seen in rats and mice,
or the opposite, it will be important to investigate the
mechanisms of action of the compound in relation to
species differences in its signalling pathway.
Pia Juul Nielsen: Your in vitro experiments with
phthalates showed adverse effects in mice, rats and
humans, therefore, it seems that these levels are not safe.
Richard Sharpe (Edinburgh, UK): There are differences
depending on the endpoint assessed. Effects are variable
for some endpoints (e.g. steroidogenesis), but there is
more consistency when looking at the effects on germ
cells. It is difficult to extrapolate from in vitro results to
the in vivo situation, however.
R Habert: Using FeTA, we were very surprised to find
that phthalates and DES did not reduce the production
of testosterone by the fetal testis in human, which is
opposite to the rat. Richard Sharpe et al. have also
observed this recently using the xenograft approach. This
is one additional validation of the in vitro approach.
Niels E Skakkebæk (Copenhagen, Denmark): Have
you found greater variability in human cultures
compared to animal cultures? There is much incon-
sistency in human populations, for example, we found a
marked variation in quality of spermatogenesis in 5000
normal young men. Is there more variation in humans
than animals? We would also expect variation in human
fetal development.
R Habert: We observe a greater variability in human
cultures than rodent ones. Humans being exposed to awww.reproduction-online.org
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stable environment can explain this. Also, the method
of preparing animal cultures is standardized but it is
variable in humans. As an example, the delay between
abortion and obtaining the fetal testes is variable. Lastly,
there are many polymorphisms in human and not in pure
rodent strains.
Niels E Skakkebæk: Although experimental proce-
dures are as constant as possible, there must be inherent
differences in the fetuses themselves, and rare cases
could have Sertoli-cell-only testes.
Richard Sharpe: There is considerable variation in the
level of testosterone production by xenografts of fetal
testes from different human fetuses in Rod Mitchell’s
xenograft studies in nude mice. We do not have an
obvious explanation for this between-fetus variation, but
it is real. All of these were normal testes with germ cells.
Ulla Hass (Søborg, Denmark): There are species
differences when comparing developmental toxicants in
humans and animals. Substances should be evaluated as
ED compounds (EDCs) if endocrine effects are seen in both
rodents and humans, even if the specific effects are different.
R Habert: Species differences do not allow us to
exclude phthalates as EDCs. Effects of phthalates largely
change as the function of the species when considering
the fetal Leydig cell function but they constantly reduce
the number of gonocytes by increasing their apoptosis in
rat, mouse and human. The rat model is relevant and
important to human risk assessment when choosing a
common effect in both species (such as gonocytes
development when considering the phthalates). The
recommended safe dose for humans is generally built
by extrapolation from animal data using a safety factor
equal to ten to account for species differences. However,
the French National Heath Safety in Food, Environment
and Work (ANSES) has recently used a factor for species
differences equal to 30 to estimate the NOAEL for BPA.
Luiz Franc¸a (Belo Horizonte, Brazil): In rats, there is a
strong interaction between macrophages and Leydig
cells. Does this have a role on the endocrine disrupting
effects of phthalates?
R Habert: We have not examined the effects of EDCs
on macrophages. Macrophages develop in vivo in the rat
fetal testis, and 20 years ago we showed that the same
development occurred in our in vitro culture system.Declaration of interest
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